Genomics Market Size, Shares and Industry Reports 2034

The global genomics market size is projected to reach USD 171.41 billion by 2034, growing from USD 44.72 billion in 2025 at a CAGR of 16.1%, driven by technological advancements, AI integration, and the rising demand for personalized medicine.

Download the Free Sample of Genomics Market Now and Get the Complete Report Easily at: https://www.towardshealthcare.com/download-sample/5065

Market Size and Growth Insights

Market Value Expansion:

●2024: USD 38.52 billion

●2025: USD 44.72 billion

●2034: USD 171.41 billion

●CAGR (2025–2034): 16.1%

Dominant Region:

●North America led the market in 2024 due to advanced infrastructure, high R&D funding, and strong adoption of precision medicine.

●Asia-Pacific projected as the fastest-growing region driven by genomics-focused government programs in India, Japan, and China.

Leading Technology:

●Polymerase Chain Reaction (PCR) held the largest market share in 2024 and is projected to be the fastest-growing technology due to accuracy, cost-effectiveness, and use in drug discovery.

Major Segments by Deliverables:

●Products: Dominated in 2024 (sequencing kits, microarray kits, reagents, and instruments).

●Services: Expected to grow steadily owing to cost-efficient outsourcing of genomic testing.

End-User Insights:

●Pharmaceutical & Biotechnology Companies: Largest contributors due to new product launches and R&D activities.

●Hospitals & Clinics: Rapidly expanding as genomics integrates with diagnostics and patient-specific treatments.

Market Trends

AI Collaboration in Genomics (NVIDIA–Illumina–Mayo Clinic, 2025):

●NVIDIA’s partnership to accelerate drug discovery with agentic AI transforms research capabilities across the $10 trillion healthcare sector.

WHO Ethical Guidelines (2024):

●Framework established for ethical genomic data use and sharing, ensuring equitable and responsible global collaboration.

Investment in AI-Powered Genomic Infrastructure (Accenture & 1910 Genetics, 2024):

●Collaboration supports AI-driven drug target identification and cost-effective therapeutics.

Government Initiatives (India, 2025):

●Launch of IBDC genomic dataset making India self-reliant in genomic data and advancing precision medicine.

Expansion of NGS (Next-Generation Sequencing):

●Enhanced accessibility due to cost reductions and improved throughput.

Multi-Omics Integration:

●Cross-disciplinary integration (proteomics, metabolomics) enhances understanding of disease mechanisms.

Rise of Functional Genomics:

●Increasing R&D in gene expression and disease cause identification accelerates market expansion.

Strategic Collaborations:

●GeneDx acquisition of Fabric Genomics (2025) merges AI interpretation and genomic medicine.

Emerging Data Privacy Regulations:

●Stricter frameworks across Europe and North America ensuring secure genomic data handling.

Shift to Clinical Implementation:

●Hospitals adopting genomic testing for chronic and rare diseases to improve diagnostic precision.

10 Deep AI Impacts and Roles in the Genomics Market

Genomic Data Interpretation:

●AI algorithms decode complex patterns across billions of sequences, enhancing diagnostic accuracy.

Predictive Disease Modeling:

●Machine learning predicts disease susceptibility, treatment responses, and hereditary risks.

3D Genome Structural Analysis:

●AI can compute thousands of 3D genome structures rapidly, supporting advanced research.

Data Integration Across EHRs:

●AI links genomic data with electronic health records to create holistic patient profiles.

Drug Discovery Optimization:

●NVIDIA’s AI accelerates drug identification and clinical trial design efficiency.

Automation of Sequencing Analysis:

●Reduces manual interpretation errors and speeds up genetic variant annotation.

AI-Powered Diagnostics:

●Models like SCADE by Valted Seq deliver real-time genomic interpretation for clinical use.

Personalized Therapy Design:

●AI tailors treatments to genetic and phenotypic profiles, enabling precision oncology.

Bioinformatics Enhancement:

●Advanced algorithms support multi-omics data integration and biomarker discovery.

Scalable Infrastructure for Genomics Data:

●AI cloud systems ensure efficient management of petabyte-scale datasets for research and clinical institutions.

Regional Insights

North America (Leading Region)

Dominance Drivers:

●Robust research funding (NHGRI budget of USD 639 million in 2025).

●Early adoption of genomic initiatives such as the Precision Medicine Initiative.

Industry Presence:

●Home to top players like Illumina, Thermo Fisher, and NVIDIA.

Regulatory Support:

●Favorable U.S. FDA approvals for gene therapies (15 approved by 2024).

Europe

●Key Markets: UK, Germany, France.

●Regulatory Framework: Strong compliance standards for genetic testing enhance reliability.

●Focus Area: Integration of genomics in national healthcare systems.

●Collaborative Programs: EU-funded research advancing personalized healthcare.

Asia-Pacific (Fastest-Growing Region)

Growth Catalysts:

●National genomic data programs (India’s IBDC, China’s genome sequencing initiatives).

●Government investments in precision medicine.

Emerging Players:

●Regional biotech startups integrating AI in sequencing.

Opportunity:

●Large population base and rising chronic disease burden.

Latin America & MEA

●Latin America: Brazil and Argentina are expanding genomic diagnostic centers.

●Middle East & Africa: UAE and Saudi Arabia investing in national genome projects, establishing data centers for precision medicine.

Market Dynamics

Drivers

●Rising prevalence of genetic disorders (70–80 million affected globally).

●Technological advancement in sequencing and PCR.

●Declining sequencing costs improving accessibility.

●Integration of genomics with precision medicine.

●Strong collaborations between AI and genomics companies.

Restraints

●Complexity in interpreting genomic data.

●Lack of skilled bioinformaticians.

●Ethical and privacy concerns.

●Inconsistent reimbursement policies.

●High initial setup costs.

Opportunities

●Multi-omics integration (genomics + proteomics + metabolomics).

●AI-driven drug discovery and diagnostics.

●Expansion in developing regions (India, China).

●New genomic data frameworks enabling global research.

●Agricultural and forensics applications expanding non-clinical revenue.

Challenges

●Data overload and limited functional variant understanding.

●Fragmented global regulatory landscape.

●Security vulnerabilities in genomic databases.

Top 10 Leading Companies in 2025

Illumina Inc.

●Product: NGS platforms and sequencing kits.

●Strength: Market leader with extensive genomic databases and collaborations (AGD initiative).

Thermo Fisher Scientific

●Product: PCR instruments, reagents, sequencing solutions.

●Strength: Global supply network and R&D dominance.

NVIDIA Corporation

●Product: AI computing platforms for genomic data.

●Strength: Industry-leading in AI-based drug discovery and healthcare partnerships.

Danaher Corporation

●Product: Genomic analysis instruments (Cytiva, Beckman Coulter brands).

●Strength: Broad biosciences portfolio and technological innovation.

Agilent Technologies

●Product: Genomic microarrays and bioinformatics software.

●Strength: Precision diagnostics and R&D collaborations.

Qiagen N.V.

●Product: Sample prep and PCR diagnostic kits.

●Strength: Expertise in molecular testing for infectious diseases.

Oxford Nanopore Technologies

●Product: Real-time sequencing devices (MinION, PromethION).

●Strength: Portable, rapid, and scalable sequencing solutions.

Bio-Rad Laboratories

●Product: Digital PCR systems and analytical tools.

●Strength: High-quality genomic testing tools for clinical diagnostics.

Eurofins Scientific

●Product: Genomic testing and laboratory services.

●Strength: Global laboratory presence and multi-industry service range.

F. Hoffmann-La Roche AG

●Product: Diagnostic kits and companion diagnostics.

●Strength: Extensive R&D collaborations (e.g., Janssen Biotech).

Latest Announcements

●10x Genomics (2025):
Announced new single-cell and spatial biology products, enhancing research scalability and data depth.

●NVIDIA (2025):
Expanded partnerships with Mayo Clinic, Illumina, and Arch Institute to drive AI transformation in genomics.

●India’s IBDC Launch (2025):
National genomic data set enabling domestic and global research independence.

Recent Developments

●Ultima Genomics (Feb 2025):
Launched UG 100 Solaris with new chemistry and software, increasing output by 50% and reducing costs by 20%.

●GeneDx Acquisition (Apr 2025):
Acquired Fabric Genomics to integrate AI in genomic interpretation.

●Fore Genomics & Inocras Partnership (Feb 2025):
Focused on enhancing pediatric genomic health screening.

●Singular Genomics Systems Acquisition (Feb 2025):
Acquired by Deerfield Management, emphasizing expansion in NGS and spatial multiomics.

●CareDx & Dovetail Genomics (Oct 2024):
Partnership for advanced HLA genotyping in transplant genomics.

●Valted Seq Launch (Apr 2025):
Introduced AI-driven Single Cell AI Discovery Engine for advanced biomarker discovery.

Segments Covered 

A. By Technology

Polymerase Chain Reaction (PCR)

●Dominance: PCR accounted for the largest market share in 2024 and is projected to remain dominant through 2034.

●Key Role: Enables the amplification of specific DNA sequences, essential for molecular diagnostics and research.

Advancements:

●Introduction of digital PCR (dPCR) and real-time PCR (qPCR) enhances accuracy and quantitative capabilities.

●Widely used in disease detection, genotyping, gene expression analysis, and mutational studies.

●Advantages: High specificity, low cost, and scalability across clinical and research environments.

●Growth Factor: Increasing usage in infectious disease diagnostics and oncology research.

Sequencing

●Core Technology: Includes Next-Generation Sequencing (NGS) and Whole Genome Sequencing (WGS).

●Key Function: Allows high-throughput analysis of genetic material, identifying mutations, and mapping genomes.

●Market Impact: Falling sequencing costs and AI integration have accelerated adoption in clinical genomics.

●Applications: Oncology, prenatal testing, pharmacogenomics, and rare disease identification.

●Future Scope: Long-read sequencing and single-cell genomics driving precision medicine advancements.

Flow Cytometry

●Purpose: Enables cell sorting, biomarker detection, and genomic profiling at the cellular level.

●Use Case: Integrates with genomics to identify gene expression patterns in specific cell populations.

●Emerging Area: Increasing use in immunogenomics and oncology diagnostics.

Microarrays

●Function: Facilitate large-scale gene profiling and expression analysis.

●Application: SNP analysis, gene expression monitoring, and epigenetic studies.

●Significance: Offers cost-effective analysis of thousands of genes simultaneously.

●Trend: Declining use in standalone form, but gaining relevance when integrated with NGS for validation.

Others (CRISPR, Bioinformatics, & Genotyping Platforms)

●CRISPR Technology: Revolutionizing genome editing for therapeutic and research purposes.

●Bioinformatics Platforms: Provide analytical tools for sequencing data interpretation.

●Emerging Technologies: Include single-cell multi-omics and high-resolution melt (HRM) assays enhancing genomic data resolution.

B. By Deliverables

Products

●Definition: Includes consumables, instruments, and software used in genomics.

Subsegments:

●Instruments/Systems/Software: Sequencers, analyzers, PCR systems, microarray scanners.

●Consumables & Reagents: Kits, buffers, enzymes, probes used for experiments.

●Dominance: Accounted for the majority market share in 2024 due to continuous usage and replacement demand.

●Applications: Core research laboratories, diagnostic centers, and pharmaceutical R&D.

●Trend: Miniaturization of devices and software integration for real-time genomic data analysis.

Services

●Definition: Outsourced or contract-based genomic analysis and sequencing services.

Subsegments:

●NGS-based Services: Whole genome and exome sequencing for healthcare and research.

●Biomarker Translation Services: Identification of biomarkers for drug response and disease prediction.

●Computational Genomics: AI-powered bioinformatics pipelines for interpreting massive data.

●Core Genomics Services: RNA/DNA extraction, library preparation, and annotation services.

●Growth Trend: Increasing outsourcing by academic institutes and small biotech companies.

●Benefit: Reduces infrastructure and expertise costs while ensuring high-quality analysis.

C. By End-Use

●Pharmaceutical & Biotechnology Companies

●Largest Segment (2024): Accounted for the highest revenue share due to extensive R&D initiatives.

●Role: Utilize genomics for target identification, biomarker discovery, and drug development.

●Growth Factor: Increasing approvals of gene therapies (15 by the U.S. FDA as of 2024).

●Infrastructure: Advanced labs, collaborations with AI firms, and regulatory support for personalized drugs.

Hospitals & Clinics

●Growth Rate: Fastest-growing end-user segment in 2024.

●Role: Adoption of genomics in diagnostics, oncology, and chronic disease management.

Drivers:

●Rising chronic disease prevalence and hospitalizations.

●Integration of genomics into patient care for personalized treatment plans.

●Reimbursement support for genetic testing.

Academic & Government Institutes

●Function: Serve as innovation hubs for genomic data generation and research.

●Key Contributors: Initiatives like NHGRI (U.S.), All of Us Research Program, and Indian Genomic Data Center (IBDC).

●Objective: Strengthen public health genomics and train next-generation scientists.

Clinical Research Organizations (CROs)

●Role: Conduct genomic studies for pharmaceutical partners, enabling faster drug trials.

●Emerging Trend: Increasing collaboration with AI-driven bioinformatics firms for data interpretation.

Others (Diagnostic Centers, Forensic Labs, Agricultural Genomics)

●Forensics: DNA fingerprinting and criminal investigation.

●Agriculture: Crop and livestock genomics improving yield and resistance.

●Diagnostics: Early disease detection through rapid sequencing platforms.

D. By Region

1. North America

Market Leadership: Largest revenue contributor in 2024.

Key Drivers:

●Advanced genomic infrastructure and funding.

●Presence of major players like Illumina, Thermo Fisher, and NVIDIA.

●Precision Medicine Initiative and “All of Us” program promoting large-scale sequencing.

Supportive Ecosystem:

●NHGRI budget increased to USD 639 million (2025).

●Regulatory clarity under the U.S. FDA for genetic therapies.

Outlook:

●Continued dominance with robust R&D collaborations between academia and industry.

2. Europe

Major Countries: UK, Germany, France, Italy, and Spain.

Growth Factors:

●National genome projects and strong ethical frameworks for data protection.

●Expanding clinical genomics testing adoption.

Healthcare Integration:

●Precision medicine incorporated into public health systems.

Research Initiatives:

●Cross-border collaborations under Horizon Europe boosting genomics innovation.

3. Asia-Pacific

Fastest-Growing Region (CAGR > 18%)

Drivers:

●Government initiatives such as India’s PRIP and IBDC genomic data program.

●Rapid adoption of sequencing in Japan and China.

●Large patient pool with genetic disorder prevalence.

Highlights:

●In March 2025, Illumina & Nashville Biosciences completed 250,000 genome sequences for AGD, aiding Asian data mapping.

Future Potential:

●Expansion of genomics startups and biobanks in emerging nations.

4. Latin America

Key Markets: Brazil and Argentina.

Focus: Adoption of genomic diagnostics in cancer and infectious disease studies.

Barriers: Limited research funding and infrastructure compared to developed regions.

Outlook: Government health programs supporting genomic literacy and genetic testing awareness.

5. Middle East & Africa (MEA)

Leading Countries: UAE, Saudi Arabia, South Africa.

Initiatives: National genome projects like the Saudi Genome Program.

Growth Drivers:

●Increasing investment in healthcare digitization.

●Expansion of medical research collaborations with U.S. and European institutes.

Challenges: Data privacy policies and shortage of bioinformatics expertise.

Top 5 FAQs

1. What is the projected market size of the genomics market by 2034?
   The market is expected to reach USD 171.41 billion by 2034 from USD 44.72 billion in 2025.

2. Which region dominates the genomics market?
   North America led in 2024, while Asia-Pacific is the fastest-growing region.

3. Which technology leads the genomics market?
   PCR technology held the largest share in 2024 and is expected to grow fastest.

4. What are the key growth drivers?
   Increasing prevalence of genetic disorders, AI integration, and demand for precision medicine.

5. Who are the major players?
   Illumina, Thermo Fisher, NVIDIA, Agilent, Qiagen, Bio-Rad, Eurofins, Danaher, Roche, and Oxford Nanopore.